NeuroNOS

Executive Summary

NeuroNOS is a preclinical-stage Israeli biotech developing a first-in-class therapeutic for Autism Spectrum Disorder (ASD) by inhibiting neuronal nitric oxide synthase (nNOS). The company's approach targets nitrosative stress, a key pathological mechanism in ASD, and has shown reversal of core ASD-like phenotypes in both mouse models and human stem cell-derived neurons. With no FDA-approved treatments for the core symptoms of ASD, NeuroNOS addresses a significant unmet medical need, offering potential disease-modifying therapy. The company was founded in 2020 and is based in Tel Aviv, currently in the preclinical stage with a small but focused team. NeuroNOS's preclinical data are compelling, demonstrating efficacy in multiple translational models. The next critical milestones include advancing toward Investigational New Drug (IND)-enabling studies and initiating first-in-human trials. While the company has not disclosed funding or valuation, the novelty of its mechanism and the strong preclinical results position it as a promising player in neurodevelopmental disorders. If successful, NeuroNOS could become a transformative therapy for ASD. Key risks include the high failure rate of CNS drugs in clinical trials and potential financing needs.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Candidate60% success
• H1 2027Partnership or Licensing Deal40% success
• H1 2027Phase 1 Clinical Trial Initiation50% success